Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
(PEGASUS Trial)
Recruiting in Palo Alto (17 mi)
+839 other locations
Overseen byMarc Sabatine, MD, MPh
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: AstraZeneca
Pivotal Trial (Near Approval)
Prior Safety Data
Approved in 2 Jurisdictions
Trial Summary
What is the purpose of this trial?
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
Eligibility Criteria
Inclusion Criteria
Person who had a heart attack within 1 - 3 years ago and at least one additional risk factor: Age ≥ 65 years old, Diabetes requiring medication, Documented history of 2nd prior MI (>1 year ago). Angiographic evidence of multivessel CAD, and / or Chronic, non-end stage renal dysfunction.
Females of child-bearing potential must have a negative pregnancy test at enrollment
Persons who are currently taking aspirin between 75 and 150 mg once daily
Treatment Details
Interventions
- Ticagrelor (P2Y12 receptor antagonist)
- Ticagrelor Placebo (Drug)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: 2Experimental Treatment1 Intervention
Oral Treatment
Group II: 1Experimental Treatment1 Intervention
Oral Treatment
Group III: 3Placebo Group1 Intervention
Oral Treatment
Ticagrelor is already approved in United States, European Union for the following indications:
🇺🇸 Approved in United States as Brilinta for:
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
🇪🇺 Approved in European Union as Brilique for:
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Research SiteDayton, OH
Research SiteJupiter, FL
Research SiteLargo, FL
Research SitePortland, OR
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
AstraZenecaLead Sponsor